Allied Blenders & Distillers
Allied Blenders & Distillers
BeveragesKey Fundamentals
SmallcapBreweries & DistilleriesBeveragesTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has delivered good profit growth of 147% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 39.3%
Weaknesses
3- Stock is trading at 10.6 times its book value
- The company has delivered a poor sales growth of 10.8% over past five years.
- Company has high debtors of 168 days.
Growth Rate
AI Analysis — Bull vs Bear
Allied Blenders & Distillers Ltd (ABDL) is a mid-cap Indian spirits company with a market capitalization of ₹16,920 Cr, trading at a PE of 81.5x and a PB of 10.3x. The company has delivered strong profit CAGR of 147% over five years but sales growth has been modest at 11% CAGR over the same period, with TTM profit growth turning negative at -7%.
- Compounded profit growth of 147% CAGR over five years signals a significant earnings turnaround from a low base
- Healthy dividend payout ratio of 39.3% indicates management commitment to returning capital to shareholders
- Dividend yield of 0.88% is reasonable for the Indian alcoholic beverages sector, which typically pays low dividends
- 3-year ROE of 14% and last year ROE of 14% show consistency in return generation
- 3-year compounded profit growth of 422% CAGR demonstrates a sharp acceleration in profitability
- Stock has delivered 16% returns over the past one year, outperforming broader market volatility
- 5-year compounded sales growth of 11% provides a stable revenue base in a sector with long-term structural tailwinds in India
- PE ratio of 81.5x is significantly elevated, implying high earnings expectations already priced in
- Price-to-book of 10.3x is steep and leaves limited margin of safety for investors
- TTM profit growth has turned negative at -7%, suggesting recent earnings momentum is fading
- Sales growth of only 8% on a TTM basis indicates a deceleration from the 5-year CAGR of 11%
- Debtor days of 168 are very high, pointing to potential working capital stress and collection risk
- 5-year sales CAGR of only 10.8% is modest for a company valued at 81.5x earnings
- ROE has remained flat at 14% over the last one and three years despite the profit surge, suggesting capital efficiency has not meaningfully improved
- Debt-to-equity ratio is unavailable, limiting visibility into the company's leverage and balance sheet risk
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Malaysia co-bottling expansion launched Aug 24
ABDL launched its first international local production arrangement in Malaysia for Officer's Choice Blue via an asset-light co-bottling model, targeting a market growing mid-teens annually. Shares surged 3.35% to ₹614.80 on the announcement.
- Q1 FY27 profit up 12% Aug 24
Standalone net profit grew 11.95% YoY to ₹68.19 crore in Q1 FY27, while total income rose 1.18% YoY to ₹1,800.28 crore. Net debt reduced by ₹33 crore to ₹947 crore as of June 30, 2026.
- Credit rating upgraded to AA- Aug 19
India Ratings upgraded ABDL's long-term bank facilities rating to IND AA- (Stable) from IND A on August 19, 2026, citing improved operating resilience.
- Officer's Choice Blue relaunched Sep 1
ABDL unveiled premium packaging for Officer's Choice Blue whisky, rolling out first in Uttar Pradesh and Maharashtra to strengthen its flagship brand positioning.
- Premium whisky The Indian Edit launched Sep 11
ABDL launched 'The Indian Edit' premium whisky on September 11, priced at ₹1,550 for 750ml in Maharashtra, blending Indian malt and grain spirits with Scotch malts for premiumization push.
- ₹125 crore malt distillery approved Sep 11
Board approved ₹125 crore investment for a 3 million litre malt distillery in Aurangabad via subsidiary Minakshi Agro, expanding backward integration capacity.
- Global reach targeting 60-70 countries Aug 24
ABDL aims to scale from 39 international markets to 60-70 countries over the next three years, having more than doubled its global reach in the past two years.
- Investor meets and roadshows scheduled Aug 19
ABDL scheduled multiple investor engagements including a non-deal roadshow in Singapore and Hong Kong (Aug 25-28), analyst meet on Aug 28, Elara conference on Sep 1, and Jefferies India Forum on Sep 18. All focused on Q1 FY27 earnings with no UPSI disclosure.
TL;DR: ABDL is executing well on multiple fronts — premiumization via new launches (The Indian Edit, Officer's Choice Blue relaunch), international expansion through an asset-light Malaysia co-bottling model, and backward integration with a ₹125 crore malt distillery. Financials are solid with 12% profit growth, debt reduction, and a two-notch credit upgrade to IND AA-. No material headwinds are visible in recent news, though revenue growth of just 1.18% YoY bears watching. The trend is clearly improving with strong international ambitions and active investor engagement signaling confidence in the growth trajectory.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 814 | 851 | 895 | 768 | 758 | 868 | 974 | 921 | 923 | 990 | 1,003 | 1,007 | 979 |
| Expenses | 762 | 780 | 836 | 708 | 683 | 764 | 857 | 785 | 811 | 865 | 867 | 838 | 863 |
| Operating Profit | 52 | 71 | 59 | 60 | 74 | 103 | 117 | 136 | 112 | 125 | 136 | 169 | 115 |
| OPM % | 6% | 8% | 7% | 8% | 10% | 12% | 12% | 15% | 12% | 13% | 14% | 17% | 12% |
| Other Income | 1 | 1 | -2 | 2 | 2 | 2 | 3 | 14 | 7 | 5 | -2 | 13 | 5 |
| Interest | 39 | 43 | 46 | 45 | 44 | 25 | 27 | 28 | 27 | 30 | 26 | 51 | 29 |
| Depreciation | 13 | 12 | 14 | 19 | 16 | 16 | 13 | 16 | 16 | 16 | 18 | 29 | 23 |
| PBT | 1 | 16 | -3 | -1 | 16 | 64 | 80 | 106 | 76 | 84 | 89 | 103 | 68 |
| Tax % | 286% | 29% | 33% | 70% | 28% | 26% | 28% | 26% | 26% | 25% | 28% | 63% | 33% |
| Net Profit | -3 | 11 | -4 | -2 | 11 | 48 | 57 | 79 | 56 | 63 | 64 | 38 | 45 |
| EPS in Rs | -0.11 | 0.46 | -0.18 | -0.1 | 0.4 | 1.7 | 2.05 | 2.81 | 2.02 | 2.3 | 2.38 | 1.46 | 1.76 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,996 | 2,348 | 2,686 | 3,147 | 3,328 | 3,520 | 3,923 | 3,979 |
| Expenses | 2,762 | 2,154 | 2,488 | 2,961 | 3,085 | 3,089 | 3,380 | 3,433 |
| Operating Profit | 234 | 195 | 197 | 186 | 243 | 431 | 542 | 546 |
| OPM % | 8% | 8% | 7% | 6% | 7% | 12% | 14% | 14% |
| Other Income | 16 | 19 | 11 | 11 | 1 | 21 | 23 | 21 |
| Interest | 180 | 142 | 146 | 136 | 173 | 126 | 135 | 137 |
| Depreciation | 69 | 59 | 59 | 55 | 58 | 61 | 79 | 86 |
| PBT | 0 | 13 | 4 | 6 | 13 | 266 | 351 | 343 |
| Tax % | -2948% | 80% | 62% | 73% | 86% | 27% | 37% | — |
| Net Profit | 13 | 3 | 1 | 2 | 2 | 195 | 220 | 210 |
| EPS in Rs | 0.54 | 0.11 | 0.06 | 0.07 | 0.07 | 6.97 | 8.16 | 7.9 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 52% | 66% | — |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 47 | 47 | 47 | 49 | 49 | 56 | 56 |
| Reserves | 326 | 328 | 357 | 357 | 358 | 1,487 | 1,607 |
| Borrowings | 1,058 | 981 | 863 | 793 | 835 | 905 | 1,151 |
| Other Liabilities | 983 | 952 | 988 | 1,301 | 1,403 | 1,086 | 1,350 |
| Total Liabilities | 2,414 | 2,308 | 2,255 | 2,500 | 2,645 | 3,534 | 4,163 |
| Fixed Assets | 636 | 649 | 692 | 575 | 635 | 749 | 889 |
| CWIP | 48 | 17 | 15 | 14 | 16 | 19 | 110 |
| Investments | 0 | 22 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,730 | 1,620 | 1,548 | 1,910 | 1,995 | 2,765 | 3,164 |
| Total Assets | 2,414 | 2,308 | 2,255 | 2,500 | 2,645 | 3,534 | 4,163 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 595 | 247 | 179 | 230 | 186 | -678 | 362 |
| Investing | -45 | -59 | 53 | -19 | -54 | -182 | -331 |
| Financing | -496 | -216 | -256 | -203 | -132 | 922 | 10 |
| Net Cash Flow | 53 | -29 | -24 | 8 | 0 | 61 | 41 |
| Free Cash Flow | 548 | 212 | 124 | 210 | 141 | -806 | 16 |
| CFO/OP | 255 | 128 | 93 | 126 | 80 | -141 | 94 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 114 | 135 | 130 | 111 | 136 | 181 | 168 |
| Inventory Days | 151 | 196 | 153 | 190 | 124 | 196 | 221 |
| Days Payable | 172 | 267 | 228 | 189 | 204 | 206 | 235 |
| Cash Conversion Cycle | 93 | 64 | 54 | 113 | 57 | 172 | 154 |
| Working Capital Days | -39 | -52 | -30 | -18 | -20 | 67 | 55 |
| ROCE % | — | 11% | 11% | 12% | 16% | 21% | 18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Allied Blenders & Distillers insights
63 extracted metrics + investor summaries across FY09–FY27.
Documents
Frequently Asked Questions about Allied Blenders & Distillers
What does Allied Blenders & Distillers Ltd do?
Where is Allied Blenders & Distillers Ltd (ABDL) listed?
Which sector does Allied Blenders & Distillers Ltd belong to?
What is the market capitalisation of Allied Blenders & Distillers Ltd?
What is the PE ratio of Allied Blenders & Distillers Ltd?
What is the 52-week high and low of Allied Blenders & Distillers Ltd?
Does Allied Blenders & Distillers Ltd pay dividends?
What is the Return on Equity (ROE) of Allied Blenders & Distillers Ltd?
Company Information
Incorporated in 2008, Allied Blenders and Distillers Ltd manufactures, purchase and sells Alcoholic Beverages /liquids[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ABDL.md for Allied Blenders & Distillers Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.